Literature DB >> 29225407

Assessing type I error and power of multistate Markov models for panel data-A simulation study.

Christy Cassarly1, Renee' H Martin1, Marc Chimowitz1, Edsel A Peña2, Viswanathan Ramakrishnan1, Yuko Y Palesch1.   

Abstract

Ordinal outcomes collected at multiple follow-up visits are common in clinical trials. Sometimes, one visit is chosen for the primary analysis and the scale is dichotomized amounting to loss of information. Multistate Markov models describe how a process moves between states over time. Here, simulation studies are performed to investigate the type I error and power characteristics of multistate Markov models for panel data with limited non-adjacent state transitions. The results suggest that the multistate Markov models preserve the type I error and adequate power is achieved with modest sample sizes for panel data with limited non-adjacent state transitions.

Entities:  

Keywords:  Multistate models; panel data; power; stroke; type I error

Year:  2016        PMID: 29225407      PMCID: PMC5722228          DOI: 10.1080/03610918.2016.1222425

Source DB:  PubMed          Journal:  Commun Stat Simul Comput        ISSN: 0361-0918            Impact factor:   1.118


  43 in total

1.  Are overweight asthmatics more difficult to control?

Authors:  P Saint-Pierre; A Bourdin; P Chanez; J-P Daures; P Godard
Journal:  Allergy       Date:  2006-01       Impact factor: 13.146

2.  Assessing the natural course of diabetic retinopathy: a population-based study in Kinmen, Taiwan.

Authors:  Tao-Hsin Tung; Shih-Jen Chen; Hui-Chuan Shih; Pesus Chou; An-Fei Li; Mong-Ping Shyong; Feng-Li Lee; Jorn-Hon Liu
Journal:  Ophthalmic Epidemiol       Date:  2006-10       Impact factor: 1.648

3.  Improving trial power through use of prognosis-adjusted end points.

Authors:  Fiona B Young; Kennedy R Lees; Christopher J Weir
Journal:  Stroke       Date:  2005-01-20       Impact factor: 7.914

4.  Simultaneous modelling of operative mortality and long-term survival after coronary artery bypass surgery.

Authors:  M Ghahramani; C B Dean; J J Spinelli
Journal:  Stat Med       Date:  2001-07-15       Impact factor: 2.373

5.  Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

Authors:  Olivia Chauvel; Karine Lacombe; Philippe Bonnard; Caroline Lascoux-Combe; Jean-Michel Molina; Patrick Miailhes; Pierre-Marie Girard; Fabrice Carrat
Journal:  Antivir Ther       Date:  2007

6.  Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials.

Authors:  Philip M W Bath; Laura J Gray; Timothy Collier; Stuart Pocock; James Carpenter
Journal:  Stroke       Date:  2007-04-26       Impact factor: 7.914

7.  Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials.

Authors:  Sean I Savitz; Robert Lew; Erich Bluhmki; Werner Hacke; Marc Fisher
Journal:  Stroke       Date:  2007-11-01       Impact factor: 7.914

8.  Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: implication for diabetic retinopathy screening in Taiwan.

Authors:  W-J Liu; L-T Lee; M-F Yen; T-H Tung; R Williams; S W Duffy; T H-H Chen
Journal:  Diabet Med       Date:  2003-09       Impact factor: 4.359

9.  Assessment of variations in control of asthma over time.

Authors:  C Combescure; P Chanez; P Saint-Pierre; J P Daurès; H Proudhon; P Godard
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

10.  Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.

Authors:  E E Elbasha; T Szucs; M A Chaudhary; Ritesh N Kumar; A Roediger; J R Cook; M Opravil
Journal:  HIV Clin Trials       Date:  2009 Jul-Aug
View more
  3 in total

1.  Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  J Biopharm Stat       Date:  2018-07-09       Impact factor: 1.051

2.  Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

3.  Duration of Carbapenemase-Producing Enterobacteriaceae Carriage in Hospital Patients.

Authors:  Yin Mo; Anastasia Hernandez-Koutoucheva; Patrick Musicha; Denis Bertrand; David Lye; Oon Tek Ng; Shannon N Fenlon; Swaine L Chen; Moi Lin Ling; Wen Ying Tang; Timothy Barkham; Niranjan Nagarajan; Ben S Cooper; Kalisvar Marimuthu
Journal:  Emerg Infect Dis       Date:  2020-09       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.